276 related articles for article (PubMed ID: 17596575)
1. Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials.
Punt CJ; Buyse M; Köhne CH; Hohenberger P; Labianca R; Schmoll HJ; Påhlman L; Sobrero A; Douillard JY
J Natl Cancer Inst; 2007 Jul; 99(13):998-1003. PubMed ID: 17596575
[TBL] [Abstract][Full Text] [Related]
2. Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials.
Bellera CA; Pulido M; Gourgou S; Collette L; Doussau A; Kramar A; Dabakuyo TS; Ouali M; Auperin A; Filleron T; Fortpied C; Le Tourneau C; Paoletti X; Mauer M; Mathoulin-Pélissier S; Bonnetain F
Eur J Cancer; 2013 Mar; 49(4):769-81. PubMed ID: 23122780
[TBL] [Abstract][Full Text] [Related]
3. Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative.
Cohen R; Vernerey D; Bellera C; Meurisse A; Henriques J; Paoletti X; Rousseau B; Alberts S; Aparicio T; Boukovinas I; Gill S; Goldberg RM; Grothey A; Hamaguchi T; Iveson T; Kerr R; Labianca R; Lonardi S; Meyerhardt J; Paul J; Punt CJA; Saltz L; Saunders MP; Schmoll HJ; Shah M; Sobrero A; Souglakos I; Taieb J; Takashima A; Wagner AD; Ychou M; Bonnetain F; Gourgou S; Yoshino T; Yothers G; de Gramont A; Shi Q; André T;
Eur J Cancer; 2020 May; 130():63-71. PubMed ID: 32172199
[TBL] [Abstract][Full Text] [Related]
4. Endpoints in cancer clinical trials.
Fiteni F; Westeel V; Pivot X; Borg C; Vernerey D; Bonnetain F
J Visc Surg; 2014 Feb; 151(1):17-22. PubMed ID: 24440056
[TBL] [Abstract][Full Text] [Related]
5. Findings from the Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group: the power of pooled individual patient data from multiple clinical trials.
Renfro LA; Sargent DJ
Chin Clin Oncol; 2016 Dec; 5(6):80. PubMed ID: 28061544
[TBL] [Abstract][Full Text] [Related]
6. Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.
Bellera CA; Penel N; Ouali M; Bonvalot S; Casali PG; Nielsen OS; Delannes M; Litière S; Bonnetain F; Dabakuyo TS; Benjamin RS; Blay JY; Bui BN; Collin F; Delaney TF; Duffaud F; Filleron T; Fiore M; Gelderblom H; George S; Grimer R; Grosclaude P; Gronchi A; Haas R; Hohenberger P; Issels R; Italiano A; Jooste V; Krarup-Hansen A; Le Péchoux C; Mussi C; Oberlin O; Patel S; Piperno-Neumann S; Raut C; Ray-Coquard I; Rutkowski P; Schuetze S; Sleijfer S; Stoeckle E; Van Glabbeke M; Woll P; Gourgou-Bourgade S; Mathoulin-Pélissier S
Ann Oncol; 2015 May; 26(5):865-872. PubMed ID: 25070543
[TBL] [Abstract][Full Text] [Related]
7. Surrogate endpoints for overall survival in lung cancer trials: a review.
Fiteni F; Westeel V; Bonnetain F
Expert Rev Anticancer Ther; 2017 May; 17(5):447-454. PubMed ID: 28399678
[TBL] [Abstract][Full Text] [Related]
8. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.
Gourgou-Bourgade S; Cameron D; Poortmans P; Asselain B; Azria D; Cardoso F; A'Hern R; Bliss J; Bogaerts J; Bonnefoi H; Brain E; Cardoso MJ; Chibaudel B; Coleman R; Cufer T; Dal Lago L; Dalenc F; De Azambuja E; Debled M; Delaloge S; Filleron T; Gligorov J; Gutowski M; Jacot W; Kirkove C; MacGrogan G; Michiels S; Negreiros I; Offersen BV; Penault Llorca F; Pruneri G; Roche H; Russell NS; Schmitt F; Servent V; Thürlimann B; Untch M; van der Hage JA; van Tienhoven G; Wildiers H; Yarnold J; Bonnetain F; Mathoulin-Pélissier S; Bellera C; Dabakuyo-Yonli TS
Ann Oncol; 2015 May; 26(5):873-879. PubMed ID: 25725046
[TBL] [Abstract][Full Text] [Related]
9. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
10. Trustworthy alteration and improvement in adjuvant treatment of colon cancer.
Harlak A; Soran A
Med Sci Monit; 2006 Mar; 12(3):RA46-52. PubMed ID: 16501433
[TBL] [Abstract][Full Text] [Related]
11. Assessment of endpoints for clinical trials for localized prostate cancer.
Schellhammer P; Cockett A; Boccon-Gibod L; Gospodarowicz M; Krongrad A; Thompson IM; Scardino P; Soloway M; Adolfsson J
Urology; 1997 Apr; 49(4A Suppl):27-38. PubMed ID: 9111612
[TBL] [Abstract][Full Text] [Related]
12. A panel discussion of controversies and challenges in the adjuvant treatment of colon cancer.
Díaz-Rubio García E; Abad Esteve A; Antón Torres A; Aranda Aguilar E; Benavides Orgaz M; Carrato Mena A; Cervantes Ruipérez A; Feliu Batle J; García Alfonso P; García Foncillas J; Grávalos Castro C; Navarro García M; Rivera Herrero F; Tabernero Caturla JM
Clin Transl Oncol; 2005; 7(1):3-11. PubMed ID: 15890149
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant therapy for stage II colon cancer after complete resection. Provincial Gastrointestinal Disease Site Group.
Figueredo A; Germond C; Maroun J; Browman G; Walker-Dilks C; Wong S
Cancer Prev Control; 1997 Dec; 1(5):379-92. PubMed ID: 9765760
[TBL] [Abstract][Full Text] [Related]
14. New adjuvant therapy for colon cancer: justified hope or commercial hype.
Galanis E; Alberts SR; O'Connell MJ
Surg Oncol Clin N Am; 2000 Oct; 9(4):813-23; discussion 825-6. PubMed ID: 11008249
[TBL] [Abstract][Full Text] [Related]
15. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.
Hudis CA; Barlow WE; Costantino JP; Gray RJ; Pritchard KI; Chapman JA; Sparano JA; Hunsberger S; Enos RA; Gelber RD; Zujewski JA
J Clin Oncol; 2007 May; 25(15):2127-32. PubMed ID: 17513820
[TBL] [Abstract][Full Text] [Related]
16. Reporting of time-to-event end points and tracking of failures in randomized trials of radiotherapy with or without any concomitant anticancer agent for locally advanced head and neck cancer.
Le Tourneau C; Michiels S; Gan HK; Siu LL
J Clin Oncol; 2009 Dec; 27(35):5965-71. PubMed ID: 19805677
[TBL] [Abstract][Full Text] [Related]
17. Statistical aspects in adjuvant and neoadjuvant trials for gastrointestinal cancer in 2020: focus on time-to-event endpoints.
Saad ED; Buyse M
Curr Opin Oncol; 2020 Jul; 32(4):384-390. PubMed ID: 32541329
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group.
Figueredo A; Charette ML; Maroun J; Brouwers MC; Zuraw L
J Clin Oncol; 2004 Aug; 22(16):3395-407. PubMed ID: 15199087
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy in locally advanced colon cancer. A phase II trial.
Jakobsen A; Andersen F; Fischer A; Jensen LH; Jørgensen JC; Larsen O; Lindebjerg J; Pløen J; Rafaelsen SR; Vilandt J
Acta Oncol; 2015 Nov; 54(10):1747-53. PubMed ID: 25920359
[TBL] [Abstract][Full Text] [Related]
20. A combined analysis of mismatch repair status and thymidylate synthase expression in stage II and III colon cancer.
Öhrling K; Karlberg M; Edler D; Hallström M; Ragnhammar P
Clin Colorectal Cancer; 2013 Jun; 12(2):128-35. PubMed ID: 23276521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
